GSK to sell two travel vaccines to Danish biotech firm
Share:
(Reuters) - GlaxoSmithKline Plc said on Monday it will sell two travel vaccines to Denmark-based biotechnology company Bavarian Nordic for an upfront payment of 301 million euros ($335.71 million). The sale of anti-rabies treatment Rabipur and Encepur, used for the prevention of tick-borne encephalitis, by the British drugmaker includes milestone payments of up to 495 million euros.